Journal
VACCINES
Volume 9, Issue 3, Pages -Publisher
MDPI
DOI: 10.3390/vaccines9030242
Keywords
African swine fever; inactivated virus; vaccine trial; domestic pigs
Categories
Funding
- Intervet International B.V. [50-2019]
- Spanish Government by the Spanish Ministry of Education, Culture and Sports
Ask authors/readers for more resources
The study aimed to test an inactivated ASFV preparation under a vaccination strategy that had not been previously tested, but the results showed that combining factors such as adjuvants, dosage, and routes of administration did not improve its protective effect, suggesting that an inactivated virus strategy may not be a viable vaccine option to fight ASF.
African swine fever (ASF) is currently the major concern of the global swine industry, as a consequence of which a reconsideration of the containment and prevention measures taken to date is urgently required. A great interest in developing an effective and safe vaccine against ASF virus (ASFV) infection has, therefore, recently appeared. The objective of the present study is to test an inactivated ASFV preparation under a vaccination strategy that has not previously been tested in order to improve its protective effect. The following have been considered: (i) virus inactivation by using a low binary ethyleneimine (BEI) concentration at a low temperature, (ii) the use of new and strong adjuvants; (iii) the use of very high doses (6 x 10(9) haemadsorption in 50% of infected cultures (HAD(50))), and (iv) simultaneous double inoculation by two different routes of administration: intradermal and intramuscular. Five groups of pigs were, therefore, inoculated with BEI- Pol16/DP/OUT21 in different adjuvant formulations, twice with a 4-week interval. Six weeks later, all groups were intramuscularly challenged with 10 HAD(50) of the virulent Pol16/DP/OUT21 ASFV isolate. All the animals had clinical signs and pathological findings consistent with ASF. This lack of effectiveness supports the claim that an inactivated virus strategy may not be a viable vaccine option with which to fight ASF.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available